# NCT06889493 (NCT06889493)

> SVV-001 With Nivolumab and Ipilimumab in Patients With Poorly Differentiated Neuroendocrine Carcinomas (NEC) or Well-Differentiated High-Grade Neuroendocrine Tumors (NET)

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT06889493
- Phase: PHASE1
- Status: RECRUITING
- Sponsor: Peter Hosein, MD
- Conditions: Neuroendocrine Carcinoma; Neuroendocrine Tumors
- Interventions: Seneca Valley Virus-001 (SVV-001); Nivolumab; Ipilimumab
- Enrollment: 36
- Primary outcome: Maximum Tolerated Dose (MTD)/Recommended Phase 2 Dose
- Primary outcome: Number of Participants Experiencing Dose Limiting Toxicities (DLTs): Part 1 Only
- Primary outcome: Number of Participants Experiencing Treatment-Related Serious Adverse Events (SAEs)
- Primary outcome: Number of Participants Experiencing Treatment-Related Adverse Events (AEs)

## Indexed commentary on NCT06889493 so far

Podcasts, YouTube videos and posts on X and Bluesky we have indexed that name the trial. LinkedIn posts are read for reports and the Enterprise MCP, not yet for this index. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- 3 posts on X

## Order

Focused, $750 at most (a smaller delivered size costs its own price): https://www.erudio.com/contact?report=nct06889493
